What the Price Implies

What the Price Implies

At $21.77, Doximity carries a market capitalization near $4.0 billion and an enterprise value near $3.2 billion against roughly $317 million of free cash flow [1] — about ten times, down from roughly 40 times at the September 2025 peak, a 70% drawdown that is almost entirely multiple compression, since free cash flow rose 19% over the same window the shares fell [2]. The reflex read is that ten times free cash flow is cheap. Whether it is turns on a single line in the cash-flow reconciliation. The $122 million of stock compensation that lifts Doximity's free cash flow to $317 million above its $196 million of net income is also what decides its valuation: on reported free cash flow it trades at ~10x, but net that compensation out and owner cash is ~$205 million — ~16x, whose steady-growth DCF is ~$21, essentially today's $21.77 price. [3] [4]

Reported free cash flow of $317 million adds back nearly $122 million of stock-based compensation. That add-back is not a bookkeeping line the cash statement is right to erase; it is a real transfer of ownership to employees that a shareholder cannot add back. Net of it, owner cash is closer to $205 million, the enterprise trades at about sixteen times that figure rather than ten, and even the steady-growth case lands near today's price rather than well above it.

The counter runs the other way, and it is not weak. The step-up in stock compensation toward the low-20s percent of revenue is guided as a discrete Pathway and AI-grant event that reverses, trending back down from FY2028; and reported free cash flow is cash the company actually collected, not an accrual — it funded $432 million of share repurchases in FY2026.

Which cash figure you capitalize is the assumption the valuation is most sensitive to, alongside the terminal growth rate. On reported free cash flow and a 3% terminal rate the steady case is worth about $31 a share; holding growth fixed and moving the discount rate from 9% to 12% ranges it from about $35 down to $25; swapping the base to SBC-adjusted owner cash brings it to about $21. The gap between "clearly cheap" and "roughly fair" is largely that single accounting choice, which is why this chapter reports both cash bases below.

The multiples

The balance sheet does most of the work in setting the frame. Doximity ended FY2026 with $748.6 million of cash, cash equivalents and marketable securities and no debt [5], so enterprise value is the market cap less roughly $0.7 billion of net cash. On 131,975,436 Class A and 50,896,611 Class B shares outstanding as of May 12, 2026 [6], the equity is worth about $4.0 billion and the enterprise about $3.2 billion.

Sources: cash and marketable securities, FY2026 10-K, Liquidity and Capital Resources [7]; share count, 10-K cover [8]; free cash flow and adjusted EBITDA, Q4 FY2026 earnings call [9]; price per NYSE market data.

These are value-stock multiples on a business that still looks like a software company underneath: 91% non-GAAP gross margins, a 55% adjusted EBITDA margin, and free cash flow at 49% of revenue in FY2026 [10]. On trailing GAAP net income of $196.1 million [11], the price-to-earnings ratio is about 20 times; on consensus FY2027 adjusted earnings near $1.43 a share, it is about 15 times. The tension in the whole chapter sits in that pairing — high-quality margins, low-growth multiples.

A growth multiple that became a value multiple

Doximity did not get cheap because the business broke. It got cheap because the market stopped paying a growth multiple for it. The stock traded at $73.15 as recently as September 30, 2025 — the date the 10-K uses to mark $9.86 billion of non-affiliate equity value [12]. At that price the enterprise was worth roughly $12.6 billion, or about 40 times the same $317 million of free cash flow that today supports a $3.2 billion enterprise value.

Source: NYSE daily closing prices; the September 30, 2025 close of $73.15 is the reference price on the FY2026 10-K cover [13].

The distinction matters for how to read the drawdown. A 70% fall driven by collapsing cash flow is a different investment than a 70% fall driven by a re-rating of unchanged cash flow — and this is the second kind. Free cash flow set a record in FY2026, engagement set records, and the shares still lost two-thirds of their value [14]. What changed was the growth rate the multiple was being applied to.

What the Street now models

The reset in the multiple tracks a reset in the forward numbers. Management's FY2027 guide is for revenue of $664 million to $676 million — 4% growth at the midpoint — with adjusted EBITDA of $323 million to $335 million, a 49% margin versus 55% in FY2026 [15]. That is the "AI investment year": revenue growth roughly flat with the overall HCP digital-ad market, which management expects to grow "at or below 5%," and profit dollars stepping down as AI compute, marketing and stock-based compensation rise [16].

Sources: FY2025–FY2026 actuals and FY2027 guidance midpoints, Q4 FY2026 earnings call [17]; FY2028 figures are consensus estimates, as reported.

Consensus adds almost nothing to that picture. The sell-side models FY2027 revenue near $672 million and adjusted EBITDA near $331 million — effectively the company's own guide — then a partial FY2028 recovery to roughly $712 million of revenue and $355 million of EBITDA. That shape is a trough followed by a modest bounce, not a re-acceleration: the Street is not underwriting AI Search as a new growth engine, it is waiting to see the current one stabilize. The direction of travel has been down. Consensus FY2027 adjusted earnings have been cut from about $1.63 ninety days ago to $1.43, and in the most recent week every one of the 19 covering analysts lowered the number. The price-target range runs from $18 to $42, with a $24.50 mean and a $24.00 median; the stock trades below both.

What $21.77 implies

Because the balance sheet holds net cash and capital intensity is negligible, the valuation reduces cleanly to a stream of free cash flow plus $0.7 billion of cash. A transparent discounted-cash-flow frame — a 10% discount rate, five years of explicit growth, then a terminal rate — brackets what the price is discounting. The three paths below are a map of the debate this report has built, not probabilities.

Source: derived from FY2026 reported free cash flow of $317 million [18] and SBC-adjusted owner cash of roughly $205 million (Cash and Buybacks); discount rate and growth assumptions in the note below.

On reported free cash flow, the flat-growth "ceiling" case is worth about $19 a share, the steady case about $31, and a genuine AI-driven re-acceleration about $45. Those three numbers sit almost exactly on the analyst target spread — the $18 low, the low-$30s that a return to durable growth would justify, and the $42 high. The current $21.77 sits between the ceiling and steady cases, nearer the ceiling: the price is discounting roughly the no-growth outcome, with the recovery and the AI upside treated as optionality rather than base case.

The balanced read

My read is that the de-rating has done its work rationally rather than overshooting. At about 10 times reported free cash flow — or roughly 16 times owner cash — for a business guided to 4% growth, with net revenue retention down to 109% and a first customer past 10% of revenue, the multiple looks closer to fair than to a bargain. A durable-but-slow-growing network monetized inside cyclical pharma budgets is worth a low-teens-to-mid-teens multiple of owner earnings, and that is roughly where it trades.

The strongest fact against that read is the quality of what got repriced. Doximity generated record free cash flow, grew it 19%, and set engagement records in the same year the multiple collapsed [19]; if commercial AI Search converts even a fraction of its claimed multibillion-dollar TAM to revenue, the steady and re-acceleration cases ($31 to $45 on reported cash) are not in the price at all. At $21.77 the option on that outcome is close to free, which is a different thing from expensive.

What would move the read is observable. Subscription growth re-accelerating toward a double-digit exit rate, or the first disclosed AI Search revenue, would pull the base case from ceiling toward steady and re-rate the multiple upward. Continued erosion — net revenue retention sliding further below 109%, owner cash falling as compute costs outrun monetization, or the 10%-plus customer renegotiating — would validate the ceiling case and make even 10 times reported free cash flow look full. The company keeps 65% of its subscription guidance booked entering the year [20], so the FY2027 prints will resolve which case is running well before the AI revenue does.